Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ºñÀΰ­¾Ï¿¡¼­ ¹æ»ç¼±Ä¡·áÀÇ ¿¹ÃøÀÎÀڷνá Ku70 ¹ßÇöÀÇ ÀÇÀÇ The Significance of Ku70 Expression in Patients with Nasopharyngeal Carcinoma

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2005³â 23±Ç 1È£ p.1 ~ 8
¼Ò¼Ó »ó¼¼Á¤º¸
¼Û½Ã¿­/Song SY ÀÌ»ó¿í/À¯Àº½Ç/Á¶°æÀÚ/¹ÚÁøÈ«/±è»óÀ±/³²¼ø¿­/À̺ÀÀç/±è¼º¹è/ÃÖ½ÂÈ£/¾È½Âµµ/½Å¼º¼ö/ÃÖÀº°æ/±èÁ¾ÈÆ

Abstract

¸ñ Àû: ¹æ»ç¼±Ä¡·á¸¦ ½ÃÇà ¹ÞÀº ºñÀΰ­¾Ï ȯÀÚ¿¡¼­ Ku70°ú DNA-PKcsÀÇ ¹ßÇö Á¤µµ°¡ ±¹¼ÒÁ¦¾îÀ²°ú Ä¡·á ½ÇÆÐ ¾ç»ó¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.

´ë»ó ¹× ¹æ¹ý: 1995³â 6¿ùºÎÅÍ 2001³â 12¿ù±îÁö ¼­¿ï¾Æ»êº´¿ø¿¡¼­ ¹æ»ç¼±Ä¡·á ´Üµ¶ ¶Ç´Â µ¿½ÃÇ×¾ÏÈ­ÇÐ-¹æ»ç¼±Ä¡·á¸¦ ½ÃÇà ¹ÞÀº 66¸íÀÇ ¿ø°ÝÀüÀÌ°¡ ¾ø´Â ºñÀΰ­¾Ï ȯÀÚ¸¦ ÈÄÇâÀûÀ¸·Î ºÐ¼®ÇÏ¿´´Ù. Áø´Ü ½Ã ¾òÀº Á¶Á÷°Ë»ç Ç¥º»¿¡¼­ Ku70°ú DNA-PKcsÀÇ ¸é¿ªÈ°¼ºµµ¸¦ ºÐ·ùÇÏ¿´´Âµ¥, ±× ±âÁØÀº ¸é¿ªÈ°¼ºµµ°¡ 50% ÀÌ»ó Ku (+)°ú, 50% ¹Ì¸¸ Ku (-) À̾ú´Ù. Ku70°ú DNA-PKcsÀÇ ¸é¿ªÈ°¼ºµµ¿Í ¹æ»ç¼±Ä¡·á¿¡ ´ëÇÑ Á¾¾çÀÇ ¹ÝÀÀ Á¤µµ¿Í Àç¹ß¾ç»ó°úÀÇ »ó°ü°ü°è¸¦ ¾Ë¾Æº¸¾ÒÀ¸¸ç, ºñÀΰ­¾ÏÀÇ ±¹¼ÒÁ¦¾îÀ²¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¿¹ÈÄÀÎÀÚ¸¦ ¾Ë¾Æº¸±â À§ÇÏ¿© ´Üº¯·®ºÐ¼®À» ½ÃÇàÇÏ¿´´Ù.

°á °ú: Ku (-) ȯÀÚ¿¡¼­ Ku (+) ȯÀÚº¸´Ù ³ôÀº 5³â ±¹¼ÒÁ¦¾îÀ²(85% vs. 42%, p=0.042)À» º¸¿´À¸³ª, ¿ø°ÝÀüÀÌÀ²Àº µÎ Áý´Ü°£¿¡ Â÷À̸¦ º¸ÀÌÁö ¾Ê¾Ò´Ù(78% vs. 82%, p=0.8672). ´Üº¯·®ºÐ¼®°á°ú Ku70ÀÇ °ú¹ßÇöÀÌ ±âÁ¸¿¡ ¾Ë·ÁÁø ºñÀΰ­¾ÏÀÇ ¿¹ÈÄÀÎÀÚº¸´Ù ¿ìÀ§¿¡ ÀÖÀ½À» ¾Ë ¼ö ÀÖ¾ú´Ù. ±¹¼ÒÀç¹ßÀ» º¸¿´´ø 22¸íÀÇ È¯ÀÚ Áß 18¸íÀÇ È¯ÀÚ¿¡¼­ Ku70 (+)À¸·Î °üÂûµÇ¾ú´Ù. DNA-PKcsÀÇ ¹ßÇö Á¤µµ´Â ¹æ»ç¼±Ä¡·á °á°ú¿¡ ¿µÇâÀ» ¹ÌÄ¡Áö ¾Ê´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù.

°á ·Ð: Ku70Àº ¿ø°ÝÀüÀÌ°¡ ¾ø´Â ºñÀΰ­¾Ï ȯÀÚ¿¡¼­ ¹æ»ç¼±Ä¡·á ´Üµ¶ ¶Ç´Â µ¿½ÃÇ×¾ÏÈ­ÇÐ-¹æ»ç¼±Ä¡·á ½ÃÇà ÀÌÈÄ Á¾¾çÀÇ ¹ÝÀÀ°ú ±¹¼ÒÁ¦¾îÀ²À» ¿¹ÃøÇÒ ¼ö ÀÖ´Â ºÐÀÚ»ý¹°ÇÐÀûÀÎ ¿¹ÃøÀÎÀÚ·Î »ç¿ëµÉ ¼ö ÀÖÀ» °ÍÀ¸·Î »ý°¢ÇÑ´Ù.

Purpose: The objective of this study was to determine whether the expressions of the two components of DNA-dependent protein kinase, Ku70 and DNA-PKcs, influence the response to radiotherapy (RT) and outcome of treatment of non-disseminated nasopharyngeal carcinoma (NPC) in patients who received definitive RT.

Materials and Methods: Sixty-six patients with NPC who were treated with radiotherapy alone or with concurrent chemotherapy between June 1995 and December 2001 were divided into groups based on the levels of immunoreactivity for Ku70 and DNA-PKcs in pretreatment biopsy specimens. The over-expression of Ku70 or DNA-PKcs groups included patients whose biopsy specimens showed at least 50% immunopositive tumor cells; patients in which less than 50% of the tumor cells in the biopsy tissues were immunopositive were placed in the low Ku70 and DNA-PKcs groups. The immunoreactivities for Ku70 and DNA-PKcs were retrospectively compared with the sensitivity of the tumor to radiation and the patterns of therapy failure. Univariate analyses were performed to determine the prognostic factors that influenced locoregional control of NPC.

Results: The five-year locoregional control rate was significantly higher in the low Ku70 group (Ku(-)) (85%) than in the high Ku70 group (Ku(+)) (42%) (p=0.0042). However, there were no differences in the metastases-free survival rates between the two groups (Ku70 (+), 82%; Ku70 (-), 78%; p=0.8672). Univariate analysis indicated that the over-expression of Ku70 surpassed other well-known predictive clinocopathologic parameters as an independent prognostic factor for locoregional control. Eighteen of 22 patients who had locoregional recurrences of the tumor displayed an over-expression of Ku70. No significant association was found between the level of DNA-PKcs expression and the clinical outcome.

Conclusion: Our data suggest that the level of Ku70 expression can be used as a molecular marker to predict the response to RT and the locoregional control after RT and concurrent chemotherapy in patients with non-disseminated NPC.

Å°¿öµå

Chemotherapy;DNA-PKcs;Immunohistochemistry;Nasopahryngeal carcinoma;Radiotherapy;Ku70;ºñÀΰ­¾Ï;¹æ»ç¼±Ä¡·á;µ¿½ÃÇ×¾ÏÈ­ÇÐ-¹æ»ç¼±Ä¡·á

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS